Julian Hitchcock, from our Life Sciences Regulatory team, highlighted the need for a public-facing inquiry at a European level that permits an analysis of what the law needs to do. He also said that with the early 2018 decision by Michal Bobek, Advocate General of the Court of Justice of the European Union, the directive ironically exempts from regulation those organisms produced by an entirely random process, but it regulates those which are actually produced by a very precise process.

You can read the full article on Labiotech.